by Cort Johnson | Aug 26, 2016 | Ampligen, Treatment
Ampligen became the first drug ever approved for use in ME/CFS when ANMAT, Argentine’s FDA, approved the drug for use in severe ME/CFS patients. The approval should provide a clear pathway for Ampligen’s approval elsewhere. The U.S. is the odd man out in... 
by Cort Johnson | Jun 25, 2016 | Ampligen, Treatment
With a UK trial for Rituximab at least temporarily in doubt, let’s turn the focus to Ampligen – a drug that is potentially one trial away from being approved for ME/CFS. Ampligen is still the only drug that’s been able to move the needle on exercise... 
by Cort Johnson | May 2, 2016 | Ampligen, Treatment
After the FDA nixed its approval for Ampligen and saddled its producer, Hemispherx Biopharma, with paying for a large new trial, it looked like Ampligen was dead and gone. Francis Collin’s promise to increase ME/CFS funding, however, caused a seismic shift in... 
by Cort Johnson | Feb 20, 2016 | Ampligen, Treatment
Bill Carter – the long-time CEO of Hemispherx Biopharma, the producer of Ampligen, was fired as the company announced new austerity measures. ME/CFS practitioners laud Ampligen but it’s never in 30 years made it to market. It’s been called “A... 
by Cort Johnson | Feb 4, 2015 | Ampligen, Gut, Homepage
Deja Vu? “I just try and not think about it, because it gets me furious” multiple sclerosis patient The story sounds eerily similar. Citing questions regarding study quality and side effects, the FDA refuses to approve a drug for a condition for which few...
